Salvianolic acid F

CAS No. 158732-59-3

Salvianolic acid F( —— )

Catalog No. M31444 CAS No. 158732-59-3

The role of our hybrid molecules, an analogue of Salvianolic acid F, in compelling the glioma cells towards apoptosis by specifically perturbing the concentration of glutathione along with caspase 6.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 235 In Stock
10MG 353 In Stock
25MG 635 In Stock
50MG 870 In Stock
100MG 1172 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Salvianolic acid F
  • Note
    Research use only, not for human use.
  • Brief Description
    The role of our hybrid molecules, an analogue of Salvianolic acid F, in compelling the glioma cells towards apoptosis by specifically perturbing the concentration of glutathione along with caspase 6.
  • Description
    The role of our hybrid molecules, an analogue of Salvianolic acid F, in compelling the glioma cells towards apoptosis by specifically perturbing the concentration of glutathione along with caspase 6.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    158732-59-3
  • Formula Weight
    314.3
  • Molecular Formula
    C17H14O6
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (318.18 mM)
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • RS5517

    RS5517 is a novel PDZ1 structural domain ligand for the study of colorectal cancer.

  • Orexin B, human TFA ...

    Orexin B, human (TFA) is an endogenous agonist at Orexin receptor with Kis of 420 and 36 nM for OX1 and OX2.

  • DCZ0415

    DCZ0415 induces antimyeloma activity in vitro, in vivo and in primary cells of drug-resistant myeloma patients. DCZ0415 is a potent TRIP13 inhibitor that can impair the repair of non-homologous end junctions and inhibit NF-κB activity.DCZ0415 (10, 20 μM; 72 hours) showed a marked reduction in colony formation, indicating that it inhibited cell proliferation.